{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:39:44Z","timestamp":1790167184258,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Western Norway Health Authority","award":["F-11314"],"award-info":[{"award-number":["F-11314"]}]},{"name":"Western Norway Health Authority","award":["507074"],"award-info":[{"award-number":["507074"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s10549-019-05294-w","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T20:33:24Z","timestamp":1559162004000},"page":"185-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database"],"prefix":"10.1007","volume":"177","author":[{"given":"Thomas","family":"Helland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari Britt","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Eimstad","family":"Haugst\u00f8yl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Terje","family":"Kval\u00f8y","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siri","family":"Lunde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Lode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragna Anne","family":"Lind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta Haga","family":"Gripsrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Jonsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Gjerde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersilia","family":"Bifulco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steinar","family":"Hustad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Jonassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turid","family":"Aas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tone Hoel","family":"Lende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst Asbj\u00f8rn","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiel Adrianus Maria","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5vard","family":"S\u00f8iland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6282-4986","authenticated-orcid":false,"given":"Gunnar","family":"Mellgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,29]]},"reference":[{"issue":"22","key":"5294_CR1","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"B Fisher","year":"2005","unstructured":"Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM et al (2005) Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Nat Cancer Inst 97(22):1652\u20131662. \n                    https:\/\/doi.org\/10.1093\/jnci\/dji372","journal-title":"J Nat Cancer Inst"},{"issue":"3","key":"5294_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000433590","volume":"10","author":"C Jackisch","year":"2015","unstructured":"Jackisch C, Harbeck N, Huober J, von Minckwitz G, Gerber B et al (2015) 14th St. Gallen International Breast Cancer Conference 2015: evidence, controversies, consensus - primary therapy of early breast cancer: opinions expressed by German experts. Breast Care 10(3):211\u2013219. \n                    https:\/\/doi.org\/10.1159\/000433590","journal-title":"Breast Care"},{"issue":"9869","key":"5294_CR3","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","volume":"381","author":"C Davies","year":"2013","unstructured":"Davies C, Pan H, Godwin J, Gray R, Arriagada R et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10\u00a0years versus stopping at 5\u00a0years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805\u2013816","journal-title":"Lancet"},{"key":"5294_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.18_suppl.5","author":"RG Gray","year":"2013","unstructured":"Gray RG, Rea D, Handley K, Bowden SJ, Perry P et al (2013) aTTom: long-term effects of continuing adjuvant tamoxifen to 10\u00a0years versus stopping at 5\u00a0years in 6,953 women with early breast cancer. J Clin Oncol. \n                    https:\/\/doi.org\/10.1200\/jco.2013.31.18_suppl.5","journal-title":"J Clin Oncol"},{"issue":"27","key":"5294_CR5","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1200\/jco.2009.25.9655","volume":"28","author":"DL Hershman","year":"2010","unstructured":"Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120\u20134128. \n                    https:\/\/doi.org\/10.1200\/jco.2009.25.9655","journal-title":"J Clin Oncol"},{"issue":"4","key":"5294_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1200\/jco.2006.10.1022","volume":"26","author":"C Owusu","year":"2008","unstructured":"Owusu C, Buist DSM, Field TS, Lash TL, Thwin SS et al (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor\u2013positive breast cancer. J Clin Oncol 26(4):549\u2013555. \n                    https:\/\/doi.org\/10.1200\/jco.2006.10.1022","journal-title":"J Clin Oncol"},{"issue":"6","key":"5294_CR7","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1200\/jop.2012.000543","volume":"8","author":"EJ Aiello Bowles","year":"2012","unstructured":"Aiello Bowles EJ, Boudreau DM, Chubak J, Yu O, Fujii M et al (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract 8(6):e149\u2013e157. \n                    https:\/\/doi.org\/10.1200\/jop.2012.000543","journal-title":"J Oncol Pract"},{"issue":"3","key":"5294_CR8","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10549-011-1893-4","volume":"132","author":"W Lorizio","year":"2012","unstructured":"Lorizio W, Wu AHB, Beattie MS, Rugo H, Tchu S et al (2012) Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat 132(3):1107\u20131118. \n                    https:\/\/doi.org\/10.1007\/s10549-011-1893-4","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"5294_CR9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.amjsurg.2006.06.018","volume":"192","author":"JR Garreau","year":"2006","unstructured":"Garreau JR, DeLaMelena T, Walts D, Karamlou K, Johnson N (2006) Side effects of aromatase inhibitors versus tamoxifen: the patients\u2019 perspective. Am J Surg 192(4):496\u2013498. \n                    https:\/\/doi.org\/10.1016\/j.amjsurg.2006.06.018","journal-title":"Am J Surg"},{"issue":"30","key":"5294_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/oxfordjournals.jncimonographs.a003450","volume":"2001","author":"PA Ganz","year":"2001","unstructured":"Ganz PA (2001) Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life. JNCI Monog 2001(30):130\u2013134. \n                    https:\/\/doi.org\/10.1093\/oxfordjournals.jncimonographs.a003450","journal-title":"JNCI Monog"},{"issue":"9793","key":"5294_CR11","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"Early Breast Cancer Trialists\u2019 Collaborative G","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative G (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771\u2013784. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(11)60993-8","journal-title":"Lancet"},{"issue":"11","key":"5294_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/FPC.0b013e3283656bc1","volume":"23","author":"DJ Klein","year":"2013","unstructured":"Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB et al (2013) PharmGKB summary: tamoxifen pathway, pharmacokinetics. Pharmacogenet Genomics 23(11):643\u2013647. \n                    https:\/\/doi.org\/10.1097\/FPC.0b013e3283656bc1","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"5294_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1046\/j.1365-2125.2002.01614.x","volume":"54","author":"JK Coller","year":"2002","unstructured":"Coller JK, Krebsfaenger N, Klein K, Endrizzi K, Wolbold R et al (2002) The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 54(2):157\u2013167","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"5294_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/annonc\/mdm434","volume":"19","author":"J Gjerde","year":"2007","unstructured":"Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE et al (2007) Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19(1):56\u201361. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdm434","journal-title":"Ann Oncol"},{"key":"5294_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13058-017-0916-4","volume":"19","author":"T Helland","year":"2017","unstructured":"Helland T, Henne N, Bifulco E, Naume B, Borgen E et al (2017) Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Breast Cancer Res 19:125. \n                    https:\/\/doi.org\/10.1186\/s13058-017-0916-4","journal-title":"Breast Cancer Res"},{"issue":"5","key":"5294_CR16","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/clpt.2011.32","volume":"89","author":"L Madlensky","year":"2011","unstructured":"Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J et al (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Therap 89(5):718\u2013725. \n                    https:\/\/doi.org\/10.1038\/clpt.2011.32","journal-title":"Clin Pharmacol Therap"},{"issue":"1","key":"5294_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/tpj.2014.34","volume":"15","author":"P Saladores","year":"2015","unstructured":"Saladores P, Murdter T, Eccles D, Chowbay B, Zgheib NK et al (2015) Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J 15(1):84\u201394. \n                    https:\/\/doi.org\/10.1038\/tpj.2014.34","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"5294_CR18","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/cpt.1007","volume":"103","author":"P Gm","year":"2018","unstructured":"Gm P, Katrin S, Henk-Jan G, Matthias S, Michael P et al (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin Pharmacol Therap 103(5):770\u2013777. \n                    https:\/\/doi.org\/10.1002\/cpt.1007","journal-title":"Clin Pharmacol Therap"},{"issue":"4","key":"5294_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.clbc.2015.04.005","volume":"15","author":"NG Jager","year":"2015","unstructured":"Jager NG, Linn SC, Schellens JH, Beijnen JH (2015) Tailored tamoxifen treatment for breast cancer patients: a perspective. Clin Breast Cancer 15(4):241\u2013244","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"5294_CR20","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/clpt.2011.153","volume":"90","author":"MF Barginear","year":"2011","unstructured":"Barginear MF, Jaremko M, Peter I, Yu C, Kasai Y et al (2011) Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Therap 90(4):605\u2013611. \n                    https:\/\/doi.org\/10.1038\/clpt.2011.153","journal-title":"Clin Pharmacol Therap"},{"issue":"24","key":"5294_CR21","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1200\/jco.2010.31.4427","volume":"29","author":"WJI Jr","year":"2011","unstructured":"Jr WJI, Walko CM, Weck KE, Ibrahim JG, Chiu WK et al (2011) Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 29(24):3232\u20133239. \n                    https:\/\/doi.org\/10.1200\/jco.2010.31.4427","journal-title":"J Clin Oncol"},{"issue":"2073","key":"5294_CR22","first-page":"3246","volume":"2017","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA et al (2017) First-in-human phase I study of the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory metastatic breast cancer. J Clin Oncol 2017(2073):3246","journal-title":"J Clin Oncol"},{"issue":"1","key":"5294_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1023\/B:BREA.0000021050.92539.b0","volume":"85","author":"L Gallicchio","year":"2004","unstructured":"Gallicchio L, Lord G, Tkaczuk K, Danton M, Lewis LM et al (2004) Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer. Breast Cancer Res Treat 85(1):89\u201397. \n                    https:\/\/doi.org\/10.1023\/B:BREA.0000021050.92539.b0","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"5294_CR24","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0009-9236(96)90108-3","volume":"59","author":"F Peyrade","year":"1996","unstructured":"Peyrade F, Frenay M, Etienne M-C, Ruch F, Guillemare C et al (1996) Age-related difference in tamoxifen disposition. Clin Pharmacol Therap 59(4):401\u2013410. \n                    https:\/\/doi.org\/10.1016\/S0009-9236(96)90108-3","journal-title":"Clin Pharmacol Therap"},{"key":"5294_CR25","doi-asserted-by":"publisher","unstructured":"Lunde S, Helland T, Jonassen J, Haugst\u00f8yl ME, Austdal M et al (2018) A prospective, longitudinal, breast cancer biobank (PBCB) in western Norway. Research Gate. \n                    https:\/\/doi.org\/10.13140\/rg.2.2.16266.11201","DOI":"10.13140\/rg.2.2.16266.11201"},{"issue":"2","key":"5294_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1023\/A:1006263818115","volume":"55","author":"LJ Fallowfield","year":"1999","unstructured":"Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D (1999) Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 55(2):189\u2013199","journal-title":"Breast Cancer Res Treat"},{"key":"5294_CR27","doi-asserted-by":"publisher","DOI":"10.5324\/nje.v18i2.23","author":"K Furu","year":"2008","unstructured":"Furu K (2008) Establishment of the nationwide Norwegian Prescription Database (NorPD)\u2013new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiologi. \n                    https:\/\/doi.org\/10.5324\/nje.v18i2.23","journal-title":"Norsk Epidemiologi"},{"issue":"1","key":"5294_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11096-013-9833-5","volume":"36","author":"LR Ayres","year":"2014","unstructured":"Ayres LR, Baldoni AdO, Borges APdS, Pereira LRL (2014) Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer. Int J Clin Pharm 36(1):45\u201354. \n                    https:\/\/doi.org\/10.1007\/s11096-013-9833-5","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"5294_CR29","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1200\/JCO.2003.07.071","volume":"21","author":"AH Partridge","year":"2003","unstructured":"Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602\u2013606. \n                    https:\/\/doi.org\/10.1200\/JCO.2003.07.071","journal-title":"J Clin Oncol"},{"key":"5294_CR30","unstructured":"NBCG (2017) National action plan with guidelines for diagnosis, treatment and follow up of breast cancer patients. vol IS-2669. Norwegian Directory of Health, \n                    www.helsedirektoratet.no"},{"issue":"1","key":"5294_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.critrevonc.2005.04.009","volume":"57","author":"CH Mom","year":"2006","unstructured":"Mom CH, Buijs C, Willemse PH, Mourits MJ, de Vries EG (2006) Hot flushes in breast cancer patients. Crit Rev Oncol\/Hematol 57(1):63\u201377. \n                    https:\/\/doi.org\/10.1016\/j.critrevonc.2005.04.009","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"21","key":"5294_CR32","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","volume":"88","author":"B Fisher","year":"1996","unstructured":"Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Nat Cancer Inst 88(21):1529\u20131542. \n                    https:\/\/doi.org\/10.1093\/jnci\/88.21.1529","journal-title":"J Nat Cancer Inst"},{"key":"5294_CR33","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1186\/1471-2407-13-612","volume":"13","author":"NG Jager","year":"2013","unstructured":"Jager NG, Koornstra RH, Vincent AD, van Schaik RH, Huitema AD et al (2013) Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites. BMC Cancer 13:612. \n                    https:\/\/doi.org\/10.1186\/1471-2407-13-612","journal-title":"BMC Cancer"},{"issue":"1","key":"5294_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1102\/1470-7330.2008.0020","volume":"8","author":"SA Polin","year":"2008","unstructured":"Polin SA, Ascher SM (2008) The effect of tamoxifen on the genital tract. Cancer Imaging 8(1):135\u2013145. \n                    https:\/\/doi.org\/10.1102\/1470-7330.2008.0020","journal-title":"Cancer Imaging"},{"issue":"8","key":"5294_CR35","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.amjhyper.2005.02.009","volume":"18","author":"K Tsuda","year":"2005","unstructured":"Tsuda K, Nishio I (2005) A selective estrogen receptor modulator, tamoxifen, and membrane fluidity of erythrocytes in normotensive and hypertensive postmenopausal women: an electron paramagnetic resonance investigation. Am J Hypertens 18(8):1067\u20131076. \n                    https:\/\/doi.org\/10.1016\/j.amjhyper.2005.02.009","journal-title":"Am J Hypertens"},{"issue":"3\u20134","key":"5294_CR36","first-page":"182","volume":"53","author":"M Suwalsky","year":"1998","unstructured":"Suwalsky M, Hernandez P, Villena F, Aguilar F, Sotomayor CP (1998) Interaction of the anticancer drug tamoxifen with the human erythrocyte membrane and molecular models. Zeitschrift fur Naturforschung C. J Biosci 53(3\u20134):182\u2013190","journal-title":"J Biosci"},{"issue":"1","key":"5294_CR37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10549-013-2422-4","volume":"138","author":"L Huiart","year":"2013","unstructured":"Huiart L, Ferdynus C, Giorgi R (2013) A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat 138(1):325\u2013328. \n                    https:\/\/doi.org\/10.1007\/s10549-013-2422-4","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"5294_CR38","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/01.mlr.0000207817.32496.cb","volume":"44","author":"R Grymonpre","year":"2006","unstructured":"Grymonpre R, Cheang M, Fraser M, Metge C, Sitar DS (2006) Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 44(5):471\u2013477. \n                    https:\/\/doi.org\/10.1097\/01.mlr.0000207817.32496.cb","journal-title":"Med Care"},{"issue":"2","key":"5294_CR39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10549-006-9193-0","volume":"99","author":"TL Lash","year":"2006","unstructured":"Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA (2006) Adherence to tamoxifen over the 5-year course. Breast Cancer Res Treat 99(2):215\u2013220. \n                    https:\/\/doi.org\/10.1007\/s10549-006-9193-0","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"5294_CR40","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1200\/jco.2001.19.2.322","volume":"19","author":"S Demissie","year":"2001","unstructured":"Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19(2):322\u2013328. \n                    https:\/\/doi.org\/10.1200\/jco.2001.19.2.322","journal-title":"J Clin Oncol"},{"issue":"1","key":"5294_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11864-017-0442-8","volume":"18","author":"M Lambertini","year":"2017","unstructured":"Lambertini M, Del Mastro L, Viglietti G, Ponde NF, Solinas C et al (2017) Ovarian function suppression in premenopausal women with early-stage breast cancer. Curr Treat Options Oncol 18(1):4. \n                    https:\/\/doi.org\/10.1007\/s11864-017-0442-8","journal-title":"Curr Treat Options Oncol"},{"issue":"10","key":"5294_CR42","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/bjc.2011.140","volume":"104","author":"L Huiart","year":"2011","unstructured":"Huiart L, Dell\u2019Aniello S, Suissa S (2011) Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. Br J Cancer 104(10):1558\u20131563. \n                    https:\/\/doi.org\/10.1038\/bjc.2011.140","journal-title":"Br J Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05294-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-019-05294-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05294-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T23:39:56Z","timestamp":1590622796000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-019-05294-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,29]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["5294"],"URL":"https:\/\/doi.org\/10.1007\/s10549-019-05294-w","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,29]]},"assertion":[{"value":"16 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Prospective Breast Cancer Biobank in which this population was obtained was approved by the Norwegian Regional Ethical Committee (2010\/1957 and 2011\/2161).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided written informed consent before enrolling. All personal identifiers for each case in this population cohort were removed before analyses.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}